MESO
Mesoblast Limited
NASDAQ · Healthcare · Biotechnology · AU
$17.32
+1.05%Year over year
Reported trailing growth
- Revenue
- +602.3%
- EBITDA
- +22.6%
- EBIT
- -7.4%
- EPS
- +48.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -87.1%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +152.5%
- EBITDA
- +41.8%
- EBIT
- +17.5%
- Net income
- +43.5%
- EPS
- +46.4%
- Free cash flow
- +11.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026